According to related industries, Tabrecta of Novartis Korea passed the D.C. of medical institutions such as the National Cancer Center, Pusan National University Hospital, Samsung Seoul Hospital, and Sinchon Severance Hospital. Tabrecta, which is currently undergoing the insurance benefit registration process, was approved in Korea in November last year.

MET mutations are rare types that account for about 3% to 4% of metastatic non-small cell lung cancer, and as there have been no treatments, interest in these new drugs is increasing. Tabrecta targets c-Met and was first approved in the United States as a non-small cell Lung Cancer treatment in May 2020.

The drug was validated by a phase